Publications-Alphamab Oncology

Publications

As of now，Alphamab Oncology owns or co-owns 41 patents worldwide related to its technology platforms and product pipelines. The R&D team has published many research papers in influential journals.

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
view more
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
view more
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
view more
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4
view more

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

Published:
The Oncologist

2021;26:e1514–e1525
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD‑L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI‑H) tumors must be delivered b...

Published:
Journal of Hematology & Oncology

2021, 14(1): 95.
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

Published:
Autophagy.

Feb. 2019; 15(7): 1258-1279.
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

Published:
Cancer Cell.

Jun. 2019;35(6):901-915.e4.
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

Published:
Molecular Cancer Therapeutics.

Jan. 2019;18(1):100-111.
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

Published:
Molecular Pharmaceutics.

Apr. 2018;15(4):1674-1681.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...

Published:
Cell Research.

Apr. 2018;28(4):416-432.
A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

Combinations of different antibodies have been shown to be more effective formanaging certain diseases than monotherapy. Co-expression of the antibody mixturein a single cell line is key to reducing ....

Published:
Journal of Biological Chemistry.

Oct. 2017 ;292(43):17885.
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achievedunprecedented success in cancer treatment over the last few years. Atezolizumabis the first PD-L1 monoclonal antibody approved...

Published:
Oncotarget.

Mar. 2017;3:17004.
Structural basis of a novel heterodimeric Fc for bispecific antibody production

Bispecific antibodies provide an efficient tool for combinational clinicaltherapy. Here we have engineered a heterodimeric Fc for bispecific antibodiesproduction by combining the knob-into-hole and .....

Published:
Oncotarget.

May. 2017 ;8(31):51037-51049.

1 2 3

PREV2/3NEXT

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD‑L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI‑H) tumors must be delivered b...

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...

A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

Combinations of different antibodies have been shown to be more effective formanaging certain diseases than monotherapy. Co-expression of the antibody mixturein a single cell line is key to reducing ....

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achievedunprecedented success in cancer treatment over the last few years. Atezolizumabis the first PD-L1 monoclonal antibody approved...

Structural basis of a novel heterodimeric Fc for bispecific antibody production

Bispecific antibodies provide an efficient tool for combinational clinicaltherapy. Here we have engineered a heterodimeric Fc for bispecific antibodiesproduction by combining the knob-into-hole and .....